

# Edward F Vonesh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5999583/publications.pdf>

Version: 2024-02-01

14  
papers

1,206  
citations

1040056

9  
h-index

1125743

13  
g-index

15  
all docs

15  
docs citations

15  
times ranked

1707  
citing authors

#	ARTICLE	IF	CITATIONS
1	Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. <i>American Journal of Kidney Diseases</i> , 2020, 75, 84-104.	1.9	311
2	Goodness-of-Fit in Generalized Nonlinear Mixed-Effects Models. <i>Biometrics</i> , 1996, 52, 572.	1.4	186
3	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1735-1745.	6.1	163
4	Shared parameter models for the joint analysis of longitudinal data and event times. <i>Statistics in Medicine</i> , 2006, 25, 143-163.	1.6	145
5	A note on the use of Laplace's approximation for nonlinear mixed-effects models. <i>Biometrika</i> , 1996, 83, 447-452.	2.4	138
6	Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system. <i>Kidney International</i> , 2014, 86, 1016-1022.	5.2	100
7	Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1756-1769.	6.1	71
8	Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. <i>BMJ Open</i> , 2019, 9, e026391.	1.9	53
9	Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. <i>Statistics in Medicine</i> , 2019, 38, 4218-4239.	1.6	32
10	Biased estimation with shared parameter models in the presence of competing dropout mechanisms. <i>Biometrics</i> , 2022, 78, 399-406.	1.4	4
11	Calculating Standard Kt/V during Hemodialysis Based on Urea Mass Removed. <i>Blood Purification</i> , 2019, 47, 62-68.	1.8	1
12	Letter by Inker et al Regarding Article, "Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure". <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008983.	3.9	1
13	On small solute clearance and patient outcomes: evidential practice or observational trepidation?. <i>Peritoneal Dialysis International</i> , 2009, 29, 623-9.	2.3	1
14	The Authors Reply. <i>Kidney International</i> , 2015, 87, 1260.	5.2	0